Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Multiple myeloma therapeutics industry is projected to witness a CAGR of 6.4% during the period 2024-2032. This growth can be ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back.

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated ...

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

More than 200 people were reported rescued from floodwaters in North Carolina following Helene’s torrential rains with more ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.